Literature DB >> 18491134

Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice.

Jiu ling Wang1, Ya qing Qie, Bing dong Zhu, Hong mei Zhang, Ying Xu, Qing zhong Wang, Jia zhen Chen, Wei Liu, Hong hai Wang.   

Abstract

Antigen 85B (Ag85B) is an important immunodominant antigen of Mycobacterium tuberculosis, and is a very promising vaccine candidate molecule. Rv3425 is a member of the subgroup 3 of the PPE family, which does not exist in all BCG strains. In this study we constructed a new rBCG which included this united gene (Ag85B-Rv3425). The level of antigen-stimulated T cells expressing IFN-gamma was significantly higher in the C57BL/6 mice vaccinated with rBCG::Ag85B-Rv3425 than with BCG. In addition, the sera from mice immunized with rBCG::Ag85B-Rv3425 revealed an increase in the specific immunoglobulin G titers than that from mice immunized with BCG. Antigen specific IgG subclass analysis showed that rBCG::Ag85B-Rv3425 tended to facilitate IgG2a production, suggesting enhancement of predominant Th1 response which in turn may facilitate increased production of protective IFN-gamma. These results suggested that this rBCG::Ag85B-Rv3425 could be a strong vaccine candidate for further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18491134     DOI: 10.1007/s00430-008-0098-x

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  27 in total

Review 1.  The immunomodulatory effects of interferon-gamma on mature B-lymphocyte responses.

Authors:  A Jurado; J Carballido; H Griffel; H K Hochkeppel; G D Wetzel
Journal:  Experientia       Date:  1989-06-15

2.  PPE protein (Rv3425) from DNA segment RD11 of Mycobacterium tuberculosis: a potential B-cell antigen used for serological diagnosis to distinguish vaccinated controls from tuberculosis patients.

Authors:  H Zhang; J Wang; J Lei; M Zhang; Y Yang; Y Chen; H Wang
Journal:  Clin Microbiol Infect       Date:  2007-02       Impact factor: 8.067

3.  Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection.

Authors:  Umaimainthan Palendira; Joanne M Spratt; Warwick J Britton; James A Triccas
Journal:  Vaccine       Date:  2005-02-25       Impact factor: 3.641

Review 4.  Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine.

Authors:  Norazmi Mohd Nor; Mustaffa Musa
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

5.  PPE antigen Rv2430c of Mycobacterium tuberculosis induces a strong B-cell response.

Authors:  Rakesh Kumar Choudhary; Sangita Mukhopadhyay; Prachee Chakhaiyar; Naresh Sharma; K J R Murthy; V M Katoch; Seyed E Hasnain
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

6.  Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.

Authors:  Ying Xu; Bingdong Zhu; Qingzhong Wang; Jiazhen Chen; Yaqing Qie; Jiuling Wang; Hongyan Wang; Baolin Wang; Honghai Wang
Journal:  FEMS Immunol Med Microbiol       Date:  2007-10-04

Review 7.  The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis.

Authors:  H G Wiker; M Harboe
Journal:  Microbiol Rev       Date:  1992-12

8.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

9.  Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis.

Authors:  Lang Bao; Wei Chen; Huidong Zhang; Xiaoying Wang
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

10.  Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis.

Authors:  Neeraj Dhar; Vivek Rao; Anil K Tyagi
Journal:  Med Microbiol Immunol       Date:  2003-08-02       Impact factor: 3.402

View more
  17 in total

Review 1.  Recent publications in medical microbiology and immunology: a retrospective.

Authors:  H W Doerr; J Cinatl
Journal:  Med Microbiol Immunol       Date:  2011-10-29       Impact factor: 3.402

2.  Mycobacterium tuberculosis region of difference (RD) 2 antigen Rv1985c and RD11 antigen Rv3425 have the promising potential to distinguish patients with active tuberculosis from M. bovis BCG-vaccinated individuals.

Authors:  Sen Wang; Jiazhen Chen; Ying Zhang; Ni Diao; Shu Zhang; Jing Wu; Chanyi Lu; Feifei Wang; Yan Gao; Lingyun Shao; Jialin Jin; Xinhua Weng; Wenhong Zhang
Journal:  Clin Vaccine Immunol       Date:  2012-11-07

3.  A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice.

Authors:  Haniyeh Aghababa; Ashraf Mohabati Mobarez; Nima Khoramabadi; Mehrdad Behmanesh; Mehdi Mahdavi; Majid Tebianian; Mehdi Nejati
Journal:  Mol Biotechnol       Date:  2014-06       Impact factor: 2.695

4.  EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A.

Authors:  Yingchun Yan; Qing-Jie Xue; Ang Liu; Hui Wang; Honghua Zhang; Shuang Wang; Longyu Zhao; Yunqing Li; Xiuzhen Li; Yuanyuan Yang; Ting Chen; Shigen Li
Journal:  Hum Vaccin Immunother       Date:  2019-10-29       Impact factor: 3.452

5.  A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.

Authors:  Chun Wang; Zhenhua Chen; Ruiling Fu; Ying Zhang; Lingxia Chen; Li Huang; Jinjin Li; Chunwei Shi; Xionglin Fan
Journal:  Med Microbiol Immunol       Date:  2011-02-22       Impact factor: 3.402

6.  Surface proteome of "Mycobacterium avium subsp. hominissuis" during the early stages of macrophage infection.

Authors:  Michael McNamara; Shin-Cheng Tzeng; Claudia Maier; Li Zhang; Luiz E Bermudez
Journal:  Infect Immun       Date:  2012-03-05       Impact factor: 3.441

7.  Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.

Authors:  Jiuling Wang; Yaqing Qie; Wei Liu; Honghai Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

8.  Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.

Authors:  Kun Tan; Jinping Liang; Xindong Teng; Xiaochun Wang; Jingyan Zhang; Xuefeng Yuan; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2013-11-05       Impact factor: 3.452

Review 9.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

Review 10.  Tuberculosis vaccine research in China.

Authors:  Douglas B Lowrie
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.